VRNA vs WVE Stock Comparison
Compare VRNA and WVE across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between VRNA and WVE?
VRNA leads the current stock comparison as Verona Pharma plc, with the clearest separation coming from risk resilience and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Verona Pharma plc vs Wave Life Sciences Ltd.
VRNA leads
VRNA leads by 3 AIQ points, primarily on Risk Resilience. Wall Street currently favors WVE on target upside.
Fragile: 2 of 5 evidence groups support VRNA.
Verona Pharma plc
Wave Life Sciences Ltd.
The Algovestiq AIQ Score currently favors VRNA over WVE, 43 versus 40 as of Sep 11, 2026. VRNA's advantage is driven primarily by stronger risk resilience, while WVE holds the stronger quality profile. Analyst target upside, however, currently favors WVE. 2 of 5 covered evidence groups favor VRNA today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 3 points. VRNA lead: Stable — the AIQ differential has held near 3 points over 30 sessions.
Compare Verona Pharma plc and Wave Life Sciences Ltd. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare VRNA and WVE against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience54 vs 40VRNA +14
- Quality47 vs 59WVE +12
- Value34 vs 34Even
2 of 5 evidence groups favor VRNA. VRNA’s edge is concentrated in risk resilience; WVE keeps a meaningful quality edge.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
No factor moved materially.
No new signals fired.
No factor moved materially.
No new signals fired.
VRNA's lead was unchanged in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — VRNA and WVE both carry a full feed there.
The central trade-off
VRNA (Verona Pharma plc): the stronger current systematic profile, led by risk resilience.
WVE (Wave Life Sciences Ltd.): the counter-case, on quality, analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
VRNAVRNA on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
VRNAVRNA on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
EvenThe two are level on Momentum.
Lower downside
VRNAVRNA on Risk Resilience, by 14 points.
Analyst upside
WVEWVE on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors VRNA, analyst targets favor WVE. That disagreement is the most useful thing on this page.
| Measure | VRNA | WVE | Note |
|---|---|---|---|
| Implied upside to target | +0.1% | +212.2% | WVE has more room |
| Target dispersion | 0% | +41.9% | Lower is tighter analyst agreement |
| Consensus | Hold | Buy | Context, not a primary driver |
| Analysts covering | 1 | 7 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
2 of 5 covered evidence groups favor VRNA. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 43 vs 40 |
| Fundamentals | VRNAon balance | revenue growth 27.3% vs -94.1%; EPS growth 166.8% vs -161.5%; TTM ROE -1.6% vs -50.1%; gross margin 95.5% vs 96.5%; operating margin 1.3% vs -3.3% — VRNA takes 4 of 5 decided legs, not all of them |
| Valuation | Even | Value 34 vs 34 |
| Technicals | Not covered | Not covered |
| Risk Resilience | VRNA | Risk Resilience 54 vs 40 |
| Analyst expectations | WVE | Target upside 0.1% vs 212.2% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of VRNA and WVE and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 3 points. (argues the conclusion is provisional)
- Only 2 of 5 covered evidence groups agree. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on VRNA.
How the comparison changed
119 daily snapshots · May 4 – Sep 10VRNA lead: Stable — the AIQ differential has held near 3 points over 30 sessions.
- Today
- VRNA +3
- 43 vs 40
- 7 sessions ago
- Level
- 43 vs 43
- 30 sessions ago
- VRNA +5
- 48 vs 43
- 90 sessions ago
- VRNA +1
- 48 vs 47
The lead changed hands 2 times in this window, most recently on Aug 11 when VRNA moved ahead of WVE.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
No active signals
0 bullish / 4 bearish / 1 neutral
- Death Cross Active — bearish, trend, long horizon (66.61%)
- 52-Week Low Proximity — bearish, risk, long horizon (0.0%)
- Downtrend Structure Active — bearish, trend, long horizon
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.71%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1WVE closes the Risk Resilience gap — currently 14 points behind, the largest single contributor to VRNA's edge.
- 2WVE's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3VRNA starts generating bearish momentum or trend signals.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
VRNA leads on balance| Metric | VRNA | WVE |
|---|---|---|
| Revenue growth (YoY) | 27.3% | -94.1% |
| EPS growth (YoY) | 166.8% | -161.5% |
| Gross margin | 95.5% | 96.5% |
| Operating margin | 1.3% | -3.3% |
| Return on equity (TTM) | -1.6% | -50.1% |
| Debt to equity | 0.88 | 0.1 |
Performance
Split across windows| Metric | VRNA | WVE |
|---|---|---|
| 1 week (5 sessions) | — | -4.3% |
| 1 month (20 sessions) | — | -10.9% |
| 3 months (63 sessions) | — | -17.5% |
| 6 months (126 sessions) | — | -66.8% |
| Year to date | — | -71.4% |
| 1 year (252 sessions) | — | -38.4% |
Technicals
Split| Metric | VRNA | WVE |
|---|---|---|
| RSI (14) | — | 30.4 |
| ADX (14) | — | 35.6 |
| Price vs 50-day | — | -17.6% |
| Price vs 200-day | — | -49.5% |
| Volatility (1M, annualized) | — | 45.1% |
Risk
VRNA is the more resilient| Metric | VRNA | WVE |
|---|---|---|
| Beta | — | 1.35 |
| Sharpe ratio | 2.17 | 0.27 |
| Sortino ratio | 3.11 | 0.57 |
| Max drawdown | -0.4% | -78.1% |
| Current drawdown | 0% | -78.1% |
| Annualized volatility | 2.2% | 168.1% |
| Value at risk (95%) | -0.2% | -5.9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, VRNA or WVE?
On the Algovestiq AIQ Score, VRNA is the stronger of the two as of Sep 11, 2026, scoring 43 against WVE's 40. The edge comes from risk resilience. WVE is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is VRNA or WVE the better buy right now?
VRNA carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Fragile — 2 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 3 points. Treat the lead as provisional.
Why does the AIQ Score favor VRNA over WVE?
The composite weights Quality, Value, Momentum and Risk Resilience. VRNA leads Risk Resilience by 14 points; WVE leads Quality by 12 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, VRNA or WVE?
Analyst price targets imply +0.1% upside for VRNA and +212.2% for WVE, so the Street currently favors WVE. That points the opposite way to the AIQ Score, which favors VRNA. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, VRNA or WVE?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, VRNA or WVE?
VRNA on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, VRNA or WVE?
The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, VRNA or WVE?
VRNA is the more resilient of the two, so the other name carries the higher downside risk. VRNA on Risk Resilience, by 14 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is VRNA more profitable than WVE?
The profitability evidence is mixed: gross margin 95.5% vs 96.5%; operating margin 1.3% vs -3.3%; ttm roe -1.6% vs -50.1%. VRNA leads on two measures and WVE on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is VRNA's lead over WVE getting stronger or weaker?
VRNA lead: Stable — the AIQ differential has held near 3 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands 2 times in that window, most recently on 2026-08-11, when VRNA moved ahead of WVE.
What would change the VRNA vs WVE verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: WVE closes the Risk Resilience gap — currently 14 points behind, the largest single contributor to VRNA's edge; WVE's Death Cross Active resolves — a bearish trend rule currently active against it; VRNA starts generating bearish momentum or trend signals; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about VRNA and WVE?
VRNA: No active signals. WVE: 0 bullish / 4 bearish / 1 neutral. On WVE it is Death Cross Active (bearish, long horizon).
Compare VRNA and WVE with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.